BOS3: Randomized Phase II/III Trial Evaluating the Efficacy of FOLFOX Alone Versus FOLFOX Plus Aflibercept in K-ras Mutant as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 13 May 2017
At a glance
- Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Liver metastases
- Focus Therapeutic Use
- Acronyms BOS3
- 19 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 27 Jul 2012 New trial record